Hester Biosciences Limited has informed the Exchange regarding Appointment of Shah & Shah Associates as Other of the company w.e.f. April 01, 2025.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts less than Nifty Microcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences announced its audited standalone and consolidated financial results for Q4 and FY ended 31 March 2025. Standalone revenue from operations grew modestly to ₹2,864.66 million in FY25 from ₹2,851.55 million in FY24, while standalone profit after tax rose 17% to ₹318.42 million from ₹271.59 million. Standalone EPS stood at ₹37.43 for FY25 versus ₹31.43 in the previous year. The Board has recommended a dividend of ₹7 per share (70%) for FY25, subject to shareholder approval. Statutory auditors Chandulal M. Shah & Co. issued an unmodified opinion on the results. The Board also appointed Shah & Shah Associates, Company Secretaries, as Secretarial Auditor for a five-year term from FY 2025-26 to FY 2029-30.
A clean audit report, a healthy 17% rise in standalone profit, and a steady 70% dividend signal operational stability and shareholder-friendly returns. Investors may view this positively, though modest top-line growth and the Tanzania forex loss of ₹20.43 million impacting consolidated results are minor concerns.